Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices.
Future Oncol
; 15(5): 459-471, 2019 Feb.
Article
en En
| MEDLINE
| ID: mdl-30251550
ABSTRACT
AIM:
To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel).METHODS:
This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017.RESULTS:
The most common first-line regimens were ipilimumab-based therapies (34%), anti-PD-1 monotherapy (26%) and BRAF/MEK inhibitor(s) (20%). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91% of BRAF-mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD-1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95% CI 16.3-23.3).CONCLUSION:
Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Pautas de la Práctica en Medicina
/
Oncología Médica
/
Melanoma
Tipo de estudio:
Observational_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos